Mll1 is essential for the senescenceassociated secretory phenotype

Genes and Development

Volumn 30, Issue 3, 2016, Pages 321-336

  Capell, Brian C ^a   Drake, Adam M ^a   Zhu, Jiajun ^a   Shah, Parisha P ^a   Dou, Zhixun ^a   Dorsey, Jean ^a   Simola, Daniel F ^a   Donahue, Greg ^a   Sammons, Morgan ^a   Rai, Taranjit Singh ^b,c   Natale, Christopher ^a   Ridky, Todd W ^a   Adams, Peter D ^b   Berger, Shelley L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

DNA damage response; Epigenetic; Inflammation; MLL1; Oncogene induced senescence; Senescence associated secretory phenotype

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANTINEOPLASTIC AGENT; DNA; ETOPOSIDE; MI 2 2; MIXED LINEAGE LEUKEMIA 1 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PROTEIN INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG; ATM PROTEIN; ATM PROTEIN, HUMAN; CELL CYCLE PROTEIN; HISTONE LYSINE METHYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MLL PROTEIN, HUMAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL AGING; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MCF 7 CELL LINE; MOUSE; NONHUMAN; ONCOGENE INDUCED SENESCENCE; ONCOLOGICAL PARAMETERS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; THERAPY INDUCED SENESCENCE; ANTAGONISTS AND INHIBITORS; CELL LINE; GENE SILENCING; GENETICS; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL AGING; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INFLAMMATION; MCF-7 CELLS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS; NF-KAPPA B; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84957805975     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.271882.115     Document Type: Article

References (67)

1. Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, et al. 2013. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 15: 978–990.
2. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J, Helin K. 2009. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A–ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171–1176.
3. Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G, Pollak MN.2012. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res 5: 536–543.
4. Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez- Niedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, et al. 2009. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23: 1177–1182.
5. Blobel GA, Kadauke S, Wang E, Lau AW, Zuber J, Chou MM, Vakoc CR. 2009. A reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Mol Cell 36: 970–983.
6. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, et al. 2015. Pharmacologic inhibition of the Menin–MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27: 589–602.
7. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Monch K, Minucci S, Porse BT, Marine JC, et al. 2007. The Polycomb group proteins bind throughout the INK4A–ARF locus and are disassociated in senescent cells. Genes Dev 21: 525–530.
8. Cahu J, Bustany S, Sola B. 2012. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 3: e446.
9. Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, et al. 2012. SASP mediates chemoresistance and tumor-initiating- activity of mesothelioma cells. Oncogene 31: 3148–3163.
10. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401–404.
11. Cerqueira A, Santamaria D, Martinez-Pastor B, Cuadrado M, Fernandez- Capetillo O, Barbacid M. 2009. Overall Cdk activity modulates the DNA damage response in mammalian cells. J Cell Biol 187: 773–780.
12. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, et al. 2011. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev 25: 2125–2136.
13. Coppe JP, Kauser K, Campisi J, Beausejour CM. 2006. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 281: 29568–29574.
14. Coppe JP, Desprez PY, Krtolica A, Campisi J. 2010. The senescence- associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99–118.
15. Coppe JP, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J. 2011. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 286: 36396–36403.
16. Crusz SM, Balkwill FR. 2015. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12: 584–596.
17. d’Adda di Fagagna F. 2008. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8: 512–522.
18. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379–384.
19. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre M, Nuciforo PG, Bensimon A, et al. 2006. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638–642.
20. Freund A, Orjalo AV, Desprez PY, Campisi J. 2010. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 16: 238–246.
21. Freund A, Patil CK, Campisi J. 2011. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 30: 1536–1548.
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.
23. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. 2015. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21: 938–945.
24. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, et al. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907–913.
25. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646–674.
26. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. 2003. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115: 565–576.
27. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X, Lei M. 2012. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482: 542–546.
28. Imai T, Yamauchi M, Seki N, Sugawara T, Saito T, Matsuda Y, Ito H, Nagase T, Nomura N, Hori T. 1996. Identification and characterization of a new gene physically linked to the ATM gene. Genome Res 6: 439–447.
29. Jenei V, Sherwood V, Howlin J, Linnskog R, Safholm A, Axelsson L, Andersson T. 2009. A t-butyloxycarbonyl-modified Wnt5aderived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci 106: 19473–19478.
30. Johnson N, Shapiro GI. 2010. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitorchemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Therap Targets 14: 1199–1212.
31. Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. 2014. In vitro cell migration and invasion assays. J Vis Exp doi: 10.3791/51046.
32. Katada S, Sassone-Corsi P. 2010. The histone methyltransferase MLL1 permits the oscillation of circadian gene expression. Nat Struct Mol Biol 17: 1414–1421.
33. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. 2008. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133: 1019–1031.
34. Laberge RM, Awad P, Campisi J, Desprez PY. 2012. Epithelial–mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron 5: 39–44.
35. Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH, Hsieh JJ. 2010. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467: 343–346.
36. Madabhushi R, Gao F, Pfenning AR, Pan L, Yamakawa S, Seo J, Rueda R, Phan TX, Yamakawa H, Pao PC, et al. 2015. Activity- inducedDNAbreaks govern the expression of neuronal early- response genes. Cell 161: 1592–1605.
37. Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, et al. 2015. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med 21: 344–352.
38. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720–724.
39. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL. 2002. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10: 1107–1117.
40. Moiseeva O, Deschenes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G. 2013. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 12: 489–498.
41. Munoz-Espin D, Serrano M. 2014. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol 15: 482–496.
42. Neves J, Demaria M, Campisi J, Jasper H. 2015. Of flies, mice, and men: evolutionarily conserved tissue damage responses and aging. Dev Cell 32: 9–18.
43. Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, et al. 2015. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520: 368–372.
44. Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. 2009. Cell surface-bound IL-1α is an upstream regulator of the senescence- associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci 106: 17031–17036.
45. Piret B, Schoonbroodt S, Piette J. 1999. The ATM protein is required for sustained activation of NF-κB following DNA damage. Oncogene 18: 2261–2271.
46. Rao RC, Dou Y. 2015. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer 15: 334–346.
47. Rodier F, Campisi J. 2011. Four faces of cellular senescence. J Cell Biol 192: 547–556.
48. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. 2009. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973–979.
49. Rogakou EP, Boon C, Redon C, Bonner WM. 1999. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146: 905–916.
50. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602.
51. Shah PP, Donahue G, Otte GL, Capell BC, Nelson DM, Cao K, Aggarwala V, Cruickshanks HA, Rai TS, McBryan T, et al. 2013. Lamin B1 depletion in senescent cells triggers largescale changes in gene expression and the chromatin landscape. Genes Dev 27: 1787–1799.
52. Shalapour S, Karin M. 2015. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125: 3347–3355.
53. Sheu JJ, Guan B, Tsai FJ, Hsiao EY, Chen CM, Seruca R, Wang TL, Shih Ie M. 2012. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am J Pathol 180: 1179–1188.
54. Shintomi K, Takahashi TS, Hirano T. 2015. Reconstitution of mitotic chromatids with a minimum set of purified factors. Nat Cell Biol 17: 1014–1023.
55. Sivakumar S, Gorbsky GJ. 2015. Spatiotemporal regulation of the anaphase-promoting complex in mitosis. Nat Rev Mol Cell Biol 16: 82–94.
56. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. 2012. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18: 1359–1368.
57. Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ. 2006. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev 20: 2397–2409.
58. Tian B, Yang Q, Mao Z. 2009. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat Cell Biol 11: 211–218.
59. van Deursen JM. 2014. The role of senescent cells in ageing. Nature 509: 439–446.
60. Walter MN,Wright KT, Fuller HR, MacNeil S, Johnson WE. 2010. Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Exp Cell Res 316: 1271–1281.
61. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. 2006. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 66: 3071–3077.
62. Wang P, Han L, Shen H, Wang P, Lv C, Zhao G, Niu J, Xue L, Wang QJ, Tong T, et al. 2014. Protein kinase D1 is essential for Rasinduced senescence and tumor suppression by regulating senescence-associated inflammation. Proc Natl Acad Sci 111: 7683–7688.
63. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. 2006. Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli. Science 311: 1141–1146.
64. Yew TL, Hung YT, Li HY, Chen HW, Chen LL, Tsai KS, Chiou SH, Chao KC, Huang TF, Chen HL, et al. 2011. Enhancement of wound healing by human multipotent stromal cell conditioned medium: the paracrine factors and p38 MAPK activation. Cell Transplant 20: 693–706.
65. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, et al. 2015. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162: 1257–1270.
66. Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12: 2997–3007.
67. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A, et al. 2015. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525: 206–211.